Join
Live feed
·
PRReleasevia Quantisnow
Kineta Inc. logo
Kintara Therapeutics Inc. logo

TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor

ByQuantisnow·Wall Street's wire, on your screen.
KA· Kineta Inc.KTRA· Kintara Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KA (Kineta Inc.), KTRA (Kintara Therapeutics Inc.) and more on Quantisnow.